Resources

Country- and Community-Led Scale-Up of Accessible, Integrated, and Family-Centered EVT Plus Services for a Healthy Start (SAFEStart+)While childhood survival rates have significantly improved in the past decade, every year, approximately five million children die before their fifth birthday—almost half are newborns in their first month of life. Vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease is a leading cause of preventable stillbirth and child mortality. Timely diagnosis and treatment of these infections are critical to protect the health and well-being of women, infants, and young children.Through partnership and funding from Unitaid, PATH and the project’s co-leads, the International Community of Women living with HIV Eastern Africa and the World Hepatitis Alliance, are leading a four-year project designed for maximum reach and impact: SAFEStart+. This project is accelerating demand and adoption of evidence-based approaches and integrated delivery strategies to eliminate vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease.SAFEStart+ is supporting countries and communities to design and scale integrated, people-centered services that meet local needs. This includes expanding access to new diagnostics that can detect multiple infections with a single test and reinforcing antenatal care services to deliver preventive treatment when it matters most.

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.To share any updates or corrections to the snapshot, please contact rsvsnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.To share any updates or corrections to the tracker, please contact rsvsnapshot@path.org.

In the Democratic Republic of the Congo (DRC), community care sites (CCS) are small health posts stationed across the country and run by two community health workers. The CCS are used to bring essential health care to hard to reach communities, especially those without an accessible health facility.PATH's Malaria Control and Elimination Partnership in Africa (MACEPA) and Rotary Healthy Communities Challenge (RHCC) teams collaborated to apply geospatial modeling to recommend strategic placement of CCS to the DRC Ministry of Health.Learn more about this process and the work in the brief below.

Africa has made significant strides toward strengthening health security. Diagnostic manufacturing capacity is expanding, and hundreds of products have received regulatory approval. Yet a critical question remains: are Africa’s diagnostic systems ready to deliver when and where they are needed most?The latest report in the Blindspots series from PATH and Impact Global Health reveals a complex picture. Drawing on data on approved diagnostics, global R&D investment trends, manufacturing capacity, and regulatory systems, the report examines how well Africa’s diagnostic ecosystem is aligned with the diseases prioritized by the Africa Centres for Disease Control and Prevention (Africa CDC).The findings reveal a persistent gap between progress and preparedness:577 diagnostics have received regulatory approval, reflecting growing product availability.Diagnostic manufacturing capacity is expanding, creating new opportunities for regional production.R&D investment continues to decline, limiting innovation and the development of future-ready tools.Nearly half of approved diagnostics remain inaccessible at the primary care level, where most people first seek healthcare.This gap highlights a critical blindspot: diagnostic readiness cannot be achieved through political commitments alone. It requires sustained investment, fit-for-purpose regulatory pathways, and financing and procurement systems that enable African manufacturers to produce and deliver the diagnostics communities need.The report identifies priority actions to strengthen Africa’s diagnostic ecosystem, including:reversing declining investment in diagnostic research and development;establishing diagnostics as a distinct regulatory category within the African Medicines Agency framework; andcreating sustainable demand, financing, and market-shaping mechanisms to support African manufacturers.The diagnostics deficit is the second publication in the Blindspots series, jointly produced by Impact Global Health and PATH, examining overlooked barriers that stand between health commitments and real-world impact.